HK Stock Market Move | WUXI XDC (02268) surged over 8% after the earnings report, with revenue of 3.701 billion yuan in the first half of the year, a year-on-year increase of 37%.

WUXI XDC (02268) surged over 8% after reporting earnings, and as of the time of this report, it is up 8.45%, at HKD 75.7, with a trading volume of HKD 350 million. In terms of news, WUXI XDC announced its interim results, with revenue of RMB 3.701 billion for the first half of the year, a year-on-year increase of 37% at actual exchange rates (AER) and 41.5% at constant exchange rates (CER); gross profit was RMB 1.371 billion, up 40.6% year-on-year; adjusted net profit attributable to shareholders was RMB 1.027 billion, an increase of 37.4% year-on-year. As of the end of the reporting period, the amount of unfulfilled service orders rose to approximately USD 2 billion, a year-on-year increase of 50.4%; if potential milestone payments are included, the total amount of unfulfilled orders is approximately USD 2.2 billion, an increase of 62.2% year-on-year. Dr. Li Jincai, CEO of WUXI XDC, stated that the company demonstrated strong performance in the first half of 2026, fully reflecting the foresight of its long-term development strategy and the strong execution capabilities of the team. Looking ahead, the group will continue to adhere to its strategy of "empowering, following, and winning in molecules," consistently empowering its clients and actively seizing significant opportunities in the increasingly vast market for bioconjugated drugs.